Rafael Cabal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rafael Cabal has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Alan Tan
Vanderbilt University Medical Center, Nashville, TN
13 shared publications - Benjamin Louis Maughan
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
13 shared publications - Diane Marie Del Valle
Icahn School of Medicine at Mount Sinai 7 Tisch Cancer Institute New York, New York
13 shared publications - Edgar Gonzalez-Kozlova
Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
13 shared publications - Geoffrey Kelly
Icahn School of Medicine at Mount Sinai 9 Human Immune Monitoring Center New York, New York
13 shared publications - Giorgio Ioannou
Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
13 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S1 shows the CONSORT diagram.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S1 shows the CONSORT diagram.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Purpose:Oxaliplatin has demonstrated the ability to sensitize tumors to immune checkpoint blockade through its immunomodulatory properties in model systems of cancer. This randomized trial aimed to evaluate gemcitabine/oxaliplatin and gemcitabine/carboplatin, each combined with nivolumab, in cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC).Patients and Methods:Cisplatin-ineligible patients with mUC were randomized 1:1 to gemcitabine/carboplatin plus nivolumab or gemcitabine/oxaliplatin plus nivolumab for up to 6 cycles, followed by nivolumab monotherapy. A pick-the-winner design was employed with objective response rate (ORR) as the primary endpoint. Secondary endpoints included progression-free survival and overall survival (OS). Exploratory analyses evaluated plasma protein analytes, circulating immune cell populations, and circulating tumor cells.Results:Forty-nine patients were enrolled (carboplatin arm, N = 25; oxaliplatin arm, N = 24). The ORRs were 69.6% [95% confidence interval (CI), 0.48–0.87] for the carboplatin arm and 33.3% (95% CI, 0.15–0.57) for the oxaliplatin arm. The median OS rates were 24.74 and 16.43 months for the carboplatin and oxaliplatin arms, respectively (hazard ratio, 1.99; 95% CI, 0.94–4.22; P = 0.07). Exploratory biomarker analyses revealed sustained adaptive immune activation in the carboplatin arm and features suggestive of tumor-promoting inflammation in the oxaliplatin arm.Conclusions:Oxaliplatin-based chemoimmunotherapy, versus carboplatin-based chemoimmunotherapy, did not yield a higher response rate, challenging assumptions based on preclinical data.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Purpose:Oxaliplatin has demonstrated the ability to sensitize tumors to immune checkpoint blockade through its immunomodulatory properties in model systems of cancer. This randomized trial aimed to evaluate gemcitabine/oxaliplatin and gemcitabine/carboplatin, each combined with nivolumab, in cisplatin-ineligible patients with metastatic urothelial carcinoma (mUC).Patients and Methods:Cisplatin-ineligible patients with mUC were randomized 1:1 to gemcitabine/carboplatin plus nivolumab or gemcitabine/oxaliplatin plus nivolumab for up to 6 cycles, followed by nivolumab monotherapy. A pick-the-winner design was employed with objective response rate (ORR) as the primary endpoint. Secondary endpoints included progression-free survival and overall survival (OS). Exploratory analyses evaluated plasma protein analytes, circulating immune cell populations, and circulating tumor cells.Results:Forty-nine patients were enrolled (carboplatin arm, N = 25; oxaliplatin arm, N = 24). The ORRs were 69.6% [95% confidence interval (CI), 0.48–0.87] for the carboplatin arm and 33.3% (95% CI, 0.15–0.57) for the oxaliplatin arm. The median OS rates were 24.74 and 16.43 months for the carboplatin and oxaliplatin arms, respectively (hazard ratio, 1.99; 95% CI, 0.94–4.22; P = 0.07). Exploratory biomarker analyses revealed sustained adaptive immune activation in the carboplatin arm and features suggestive of tumor-promoting inflammation in the oxaliplatin arm.Conclusions:Oxaliplatin-based chemoimmunotherapy, versus carboplatin-based chemoimmunotherapy, did not yield a higher response rate, challenging assumptions based on preclinical data.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S3 shows peripheral immune cell changes of the two groups.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S3 shows peripheral immune cell changes of the two groups.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S2 shows CyTOF panel and cell cluster definitions.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S2 shows CyTOF panel and cell cluster definitions.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S4 shows representativeness of study participants.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S4 shows representativeness of study participants.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S1 shows the Olink IO panel analytes.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S1 shows the Olink IO panel analytes.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S4 shows correlation between Olink and overall survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S4 shows correlation between Olink and overall survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S6 shows correlation between CTC and overall survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Figure S6 shows correlation between CTC and overall survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S3 shows detailed power calculation.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Table S3 shows detailed power calculation.